AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
Overall FOLD gets a fundamental rating of 4 out of 10. We evaluated FOLD against 558 industry peers in the Biotechnology industry. Both the profitability and the financial health of FOLD get a neutral evaluation. Nothing too spectacular is happening here. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
FOLD had a positive operating cash flow in the past year.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
FOLD's Return On Assets of -3.72% is amongst the best of the industry. FOLD outperforms 87.99% of its industry peers.
With an excellent Return On Equity value of -15.18%, FOLD belongs to the best of the industry, outperforming 87.28% of the companies in the same industry.
FOLD has a Return On Invested Capital of 5.93%. This is amongst the best in the industry. FOLD outperforms 93.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROIC | 5.93% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 8.80%, FOLD belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
The Gross Margin of FOLD (90.60%) is better than 92.83% of its industry peers.
FOLD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
FOLD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FOLD has an improved debt to assets ratio.
2.2 Solvency
FOLD has an Altman-Z score of -1.70. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
FOLD's Altman-Z score of -1.70 is in line compared to the rest of the industry. FOLD outperforms 56.27% of its industry peers.
The Debt to FCF ratio of FOLD is 242.98, which is on the high side as it means it would take FOLD, 242.98 years of fcf income to pay off all of its debts.
FOLD has a Debt to FCF ratio of 242.98. This is amongst the best in the industry. FOLD outperforms 90.86% of its industry peers.
A Debt/Equity ratio of 2.02 is on the high side and indicates that FOLD has dependencies on debt financing.
The Debt to Equity ratio of FOLD (2.02) is worse than 81.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Altman-Z | -1.7 |
ROIC/WACC0.62
WACC9.56%
2.3 Liquidity
A Current Ratio of 3.34 indicates that FOLD has no problem at all paying its short term obligations.
FOLD has a worse Current ratio (3.34) than 61.47% of its industry peers.
A Quick Ratio of 2.47 indicates that FOLD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.47, FOLD is not doing good in the industry: 68.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 81.63% over the past year.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.26%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 76.15% on average per year.
FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.94% yearly.
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue Next Year17.78%
Revenue Next 2Y20.45%
Revenue Next 3Y20.92%
Revenue Next 5Y19.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
FOLD is valuated rather expensively with a Price/Forward Earnings ratio of 21.51.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 91.76% of the companies listed in the same industry.
FOLD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.27, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, FOLD is valued cheaper than 92.65% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, FOLD is valued cheaper than 90.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1082.92 | ||
| EV/EBITDA | 32.66 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 79.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.03%
EPS Next 3Y79.24%
5. Dividend
5.1 Amount
No dividends for FOLD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:FOLD (6/24/2025, 9:44:07 AM)
5.655
-0.05 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.99%
Inst Owner Change4.29%
Ins Owners0.6%
Ins Owner Change15.33%
Market Cap1.74B
Analysts82.22
Price Target15.98 (182.58%)
Short Float %7.02%
Short Ratio4.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)106.71%
Min EPS beat(2)-26.06%
Max EPS beat(2)239.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)-0.84%
Revenue beat(4)2
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)2.52%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)6
Avg Revenue beat(12)-1.43%
Revenue beat(16)8
Avg Revenue beat(16)-1.23%
PT rev (1m)-0.84%
PT rev (3m)-4.73%
EPS NQ rev (1m)-16.48%
EPS NQ rev (3m)-1137.35%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-176.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.85%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-1.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.51 | ||
| P/S | 3.21 | ||
| P/FCF | 1082.92 | ||
| P/OCF | 488.87 | ||
| P/B | 9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 32.66 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.26
Fwd EY4.65%
FCF(TTM)0.01
FCFY0.09%
OCF(TTM)0.01
OCFY0.2%
SpS1.76
BVpS0.63
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROCE | 7.5% | ||
| ROIC | 5.93% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 21.92% | ||
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% | ||
| FCFM | 0.3% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Debt/EBITDA | 6.97 | ||
| Cap/Depr | 23.74% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 6.36% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | -1.7 |
F-Score7
WACC9.56%
ROIC/WACC0.62
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
Revenue Next Year17.78%
Revenue Next 2Y20.45%
Revenue Next 3Y20.92%
Revenue Next 5Y19.94%
EBIT growth 1Y179.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.34%
EBIT Next 3Y110.27%
EBIT Next 5YN/A
FCF growth 1Y101.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.82%
OCF growth 3YN/A
OCF growth 5YN/A